UY34847A - Preparacion sólida - Google Patents

Preparacion sólida

Info

Publication number
UY34847A
UY34847A UY0001034847A UY34847A UY34847A UY 34847 A UY34847 A UY 34847A UY 0001034847 A UY0001034847 A UY 0001034847A UY 34847 A UY34847 A UY 34847A UY 34847 A UY34847 A UY 34847A
Authority
UY
Uruguay
Prior art keywords
solid preparation
present
saccharide
methyl
salt
Prior art date
Application number
UY0001034847A
Other languages
English (en)
Inventor
Misaki Masafumi
Takahara Maiko
Yamane Ikurou
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of UY34847A publication Critical patent/UY34847A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2813—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones

Abstract

La presente invención proporciona una preparación sólida con excelentes propiedades de desintegración y estabilidad de preservación. La presente inv ención se refiere a una preparación sólida que contiene (1) 2-[[6-[(3R)-3-amino-1-piperidinil]-3,4-dihidro-3-metil-2,4-dioxo-1(2H)-pirimidinil]metil]-4-fluorobenzonitrilo (compuesto(A)) o una sal del mismo, (2) un sacárido, y (3) fumarato de estearil sodio. Además, la presente invención se refiere a una preparación sólida que contiene (1) compuesto (A) o una sal del mismo, (2) un sacárido, y (3) ácido esteárico o talco en una parte de un comprimido desnudo.
UY0001034847A 2012-06-05 2013-06-04 Preparacion sólida UY34847A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2012128360 2012-06-05

Publications (1)

Publication Number Publication Date
UY34847A true UY34847A (es) 2014-01-31

Family

ID=48670046

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001034847A UY34847A (es) 2012-06-05 2013-06-04 Preparacion sólida

Country Status (10)

Country Link
US (2) US9486411B2 (es)
EP (1) EP2854772A1 (es)
JP (1) JP6122879B2 (es)
KR (1) KR102145641B1 (es)
CN (1) CN104519874B (es)
AR (1) AR092843A1 (es)
CA (1) CA2874820C (es)
TW (1) TWI580444B (es)
UY (1) UY34847A (es)
WO (1) WO2013183784A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020090971A1 (ja) * 2018-10-31 2020-05-07 富士フイルム株式会社 抗腫瘍剤を含む錠剤
WO2020090970A1 (ja) * 2018-10-31 2020-05-07 富士フイルム株式会社 抗腫瘍剤を含む医薬組成物

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997010224A1 (en) 1995-09-13 1997-03-20 Takeda Chemical Industries, Ltd. Benzoxazepine compounds, their production and use as lipid lowering agents
AR035016A1 (es) 1999-08-25 2004-04-14 Takeda Chemical Industries Ltd Composicion de azol promotor de produccion/secrecion de neurotrofina, compuesto prodroga del mismo, composicion farmaceutica que lo comprende y uso del mismo para preparar esta ultima.
AU2001248751A1 (en) * 2000-04-12 2001-10-23 Banyu Pharmaceutical Co. Ltd. Compositions disintegrating in oral cavity and preparations disintegrating in oral cavity
AR029538A1 (es) 2000-07-06 2003-07-02 Wyeth Corp Composiciones farmaceuticas de agentes estrogenicos
CA2416384A1 (en) 2000-07-17 2003-01-16 Takeda Chemical Industries, Ltd. Sulfone derivatives, their production and use
NZ540381A (en) 2002-11-01 2007-11-30 Takeda Pharmaceutical 5-membered aromatic heterocycle derivatives as prophylactic and therapeutic agents for treating neuropathy
CA2505322A1 (en) 2002-11-08 2004-05-21 Takeda Pharmaceutical Company Limited Receptor function regulator
CA2507026A1 (en) 2002-11-22 2004-06-10 Takeda Pharmaceutical Company Limited Imidazole derivatives, their production and use
WO2004106276A1 (ja) 2003-05-30 2004-12-09 Takeda Pharmaceutical Company Limited 縮合環化合物
WO2005030740A1 (ja) 2003-09-30 2005-04-07 Takeda Pharmaceutical Company Limited チアゾリン誘導体およびその用途
CA2550012A1 (en) 2003-12-17 2005-06-30 Takeda Pharmaceutical Company Limited Urea derivative, process for producing the same and use
US7456218B2 (en) 2003-12-25 2008-11-25 Takeda Pharmaceutical Company Limited 3-(4-benzyloxyphenyl) propanoic acid derivatives
WO2005063725A1 (ja) 2003-12-26 2005-07-14 Takeda Pharmaceutical Company Limited フェニルプロパン酸誘導体
SI1715893T1 (sl) 2004-01-20 2009-12-31 Novartis Pharma Ag Direktna kompresijska formulacija in postopek
US7786165B2 (en) 2004-03-15 2010-08-31 Takeda Pharmaceutical Company Limited Aminophenylpropanoic acid derivative
AU2004318013B8 (en) 2004-03-15 2011-10-06 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
JP4859665B2 (ja) 2004-03-30 2012-01-25 武田薬品工業株式会社 アルコキシフェニルプロパン酸誘導体
TWI396686B (zh) 2004-05-21 2013-05-21 Takeda Pharmaceutical 環狀醯胺衍生物、以及其製品和用法
GT200600008A (es) 2005-01-18 2006-08-09 Formulacion de compresion directa y proceso
EP1873144B1 (en) 2005-04-20 2014-07-23 Takeda Pharmaceutical Company Limited Fused heterocyclic compound
WO2007013694A1 (ja) 2005-07-29 2007-02-01 Takeda Pharmaceutical Company Limited フェノキシアルカン酸化合物
EP1916234B1 (en) 2005-07-29 2014-11-12 Takeda Pharmaceutical Company Limited Cyclopropanecarboxylic acid compound
BRPI0615150A2 (pt) 2005-08-10 2017-06-20 Takeda Pharmaceuticals Co agente para a profilaxia ou tratamento de diabete, sensibilizador de insulina, composto, pró-droga, agente farmacêutico, e, uso do composto ou um sal do mesmo ou uma pró-droga do mesmo
JP2007063225A (ja) 2005-09-01 2007-03-15 Takeda Chem Ind Ltd イミダゾピリジン化合物
WO2007033350A1 (en) 2005-09-14 2007-03-22 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors for treating diabetes
EP1924567B1 (en) 2005-09-16 2012-08-22 Takeda Pharmaceutical Company Limited Process for the preparation of pyrimidinedione derivatives
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
PE20080993A1 (es) 2006-06-27 2008-10-06 Takeda Pharmaceutical Compuestos ciclicos fusionados como moduladores del receptor gpr40
AR062760A1 (es) 2006-09-13 2008-12-03 Takeda Pharmaceutical Administracion de inhibidores de dipeptidilpetidasa
EP2298772A1 (en) 2006-10-18 2011-03-23 Takeda Pharmaceutical Company Limited Fused heterocyclic compounds
US8410087B2 (en) 2006-10-19 2013-04-02 Takeda Pharmaceutical Company Limited Indole compound
TW200838536A (en) 2006-11-29 2008-10-01 Takeda Pharmaceutical Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
US20100016396A1 (en) 2007-01-29 2010-01-21 Hiroshi Imoto Pyrazole compound
WO2008099794A1 (en) 2007-02-09 2008-08-21 Takeda Pharmaceutical Company Limited Fused ring compounds as partial agonists of ppar-gamma
JP5432720B2 (ja) * 2007-03-13 2014-03-05 武田薬品工業株式会社 ２−［［６−［（３ｒ）−３−アミノ−１−ピペリジニル］−３，４−ジヒドロ−３−メチル−２，４−ジオキソ−１（２ｈ）−ピリミジニル］メチル］−４−フルオロベンゾニトリルを含む固形製剤
JPWO2008136428A1 (ja) 2007-04-27 2010-07-29 武田薬品工業株式会社 含窒素５員複素環化合物
JP2011502958A (ja) 2007-06-19 2011-01-27 武田薬品工業株式会社 グルコキナーゼ活性化インダゾール化合物
WO2009144974A1 (ja) * 2008-05-29 2009-12-03 第一三共株式会社 製剤における滑沢剤成分の混合状態をモニターする方法
MX2012001284A (es) 2009-07-28 2012-03-26 Takeda Pharmaceutical Tableta.
JP5421945B2 (ja) * 2010-03-10 2014-02-19 大日本住友製薬株式会社 イルベサルタンとアムロジピンまたはその塩を含有する医薬組成物
WO2012062691A1 (en) * 2010-11-09 2012-05-18 F. Hoffmann-La Roche Ag Pharmaceutical compositions for treating hcv infections

Also Published As

Publication number Publication date
JP2015518815A (ja) 2015-07-06
JP6122879B2 (ja) 2017-04-26
KR102145641B1 (ko) 2020-08-18
KR20150021544A (ko) 2015-03-02
US20150141447A1 (en) 2015-05-21
US9757377B2 (en) 2017-09-12
TW201400147A (zh) 2014-01-01
CA2874820A1 (en) 2013-12-12
WO2013183784A1 (en) 2013-12-12
CA2874820C (en) 2020-06-09
TWI580444B (zh) 2017-05-01
EP2854772A1 (en) 2015-04-08
US9486411B2 (en) 2016-11-08
CN104519874B (zh) 2018-08-03
CN104519874A (zh) 2015-04-15
AR092843A1 (es) 2015-05-06
US20170007607A1 (en) 2017-01-12

Similar Documents

Publication Publication Date Title
PH12014502280A1 (en) Indole and indazole compounds that activate ampk
AR065698A1 (es) Preparacion solida
CA2871471C (en) Dna-pk inhibitors
BR112015020466A2 (pt) inibidores de cdc7
EA201270204A1 (ru) Таблетка
PE20140923A1 (es) Preparacion solida que comprende alogliptina y clorhidrato de metformina
MX355739B (es) Composiciones y articulos para el cuidado personal.
GEP20166554B (en) Nitrogenated heterocyclic compound
BR112014005226A2 (pt) derivados de benzonitrila como inibidores de cinase
EA201100580A1 (ru) Имидазопиридазинкарбонитрилы, используемые в качестве ингибиторов киназы
BR112013028449A2 (pt) composições compreendendo partículas de hidrogel
MX2013001361A (es) 4-(1h-indol-3-il) - pirimidina como inhibidores de alk.
MY180165A (en) Heteroaryl butanoic acid derivatives as lta4h inhibitors
BR112014026828A2 (pt) compostos de triazolo como inibidores de pde10
BR112013022213A2 (pt) administração parenteral de tapentadol
BR112015008389A2 (pt) compostos úteis na síntese de compostos de benzamida
EA201500245A1 (ru) Твердый фармацевтический препарат, который содержит левотироксин
AR090073A1 (es) N-etil-n-fenil-1,2-dihidro-4,5-di-hidroxi-1-metil-2-oxo-3-quinolinacarboxamida, su preparacion y usos
CA2922375C (en) Alpha-tea salt forms: compositions and uses for treating disease
UY34847A (es) Preparacion sólida
BR112015020076A2 (pt) composição agroquímica suspensa aquosa
BR112015023078A2 (pt) inibidores de pirrolopirimindina cdk9 quinase
MY182801A (en) Compound for activating ampk and uses thereof
TWD164987S (zh) 插頭之部分
UA87771C2 (ru) Лекарственное средстве в форме таблетки на основе валацикловира гидрохлорида моногидрата

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20210528